CheckMyRecalls

Samsung Bioepis Co., Ltd. recalls HADLIMA (adalimumab-bwwd) injection

Published
5 Nov 2025
Units affected
5,518 packs (11,036 Syringes) 2 syringes/carton)
Agency
FDA
Country
United States

The hazard

Lack of Assurance of Sterility.

Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.

What to do

Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.

  • Check the lot number on the box or bottle.
  • Talk to your pharmacist or doctor before stopping any prescribed medicine.
  • Return the product to the pharmacy for safe disposal.
Read the official FDA notice

Product details

HADLIMA (adalimumab-bwwd) injection, 40mg/0.8 mL, 2 Single-dose Prefilled Syringes per carton, Rx only, Manufactured for: Organon LLC, a subsidiary of ORGANON & Co, Jersey City, NJ 07302, Manufactured by: SAMSUN BIOEPIS Co., Ltd, Incheon, Republic of Korea, NDC 78206-183-01.

Brand / company
Samsung Bioepis Co., Ltd.
Codes / lots
Lot: F2505017, Expiry: 24-Jan-2027
Distribution
Distributed only to one warehouse in NJ. with no further distribution
Recall status
Ongoing

Source: U.S. Food and Drug Administration, published 5 Nov 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.